Table 3.
Laboratory evaluation and clinical follow-up of individuals who are prescribed PrEP
| Test | Baseline (Week 0) | About day 30 after initiating PrEP (optional) | 90 days after initiating PrEP | Every subsequent 90 days on PrEP | Other frequency |
|---|---|---|---|---|---|
| HIV testing and assessment for signs or symptoms of acute infection | Y | Y | Y | Y | N |
| Assess side effects | N | Y | Y | Y | N |
| Hepatitis B serology | Y | N | N | N | N |
| Hepatitis C serology | Y | N | N | N | At least every 12 months |
| STI (i.e. syphilis, gonorrhoea, chlamydia) as per Australian STI Management Guidelines [9] | Y | N | Y | Y | N |
| eGFR and urine protein: creatinine ratio (PCR) at 3 months and then every 6 months | Y | N | Y | N | At least every 6 months |
| Pregnancy test (for women of child-bearing potential) | Y | Y | Y | Y | N |